Sanofi, UCB to Seek Anti-Inflammatory Small Molecules
March 11 2014 - 03:04AM
Dow Jones News
PARIS--French pharmaceutical company Sanofi SA (SAN.FR) and
Belgium's UCB (UCB.BT) Tuesday agreed to jointly seek and develop
new anti-inflammatory molecules to treat immune-mediated diseases
in areas like gastroenterology and arthritis.
Sanofi and UCB will share costs and profits equally and UCB will
be paid to for preclinical and clinical development that may
surpass 100 million euros ($139 million).
Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2023 to Mar 2024